InterMune abandons Actimmune as fibrosis treatment

03/6/2007 | NYTimes.com

InterMune says late-stage clinical trial results showed Actimmune did not prolong the lives of those suffering from idiopathic pulmonary fibrosis any better than a placebo. The company has another pulmonary fibrosis drug, pirfenidone, in late-stage trials.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA